Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 1:00 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presenta.

Zoetis to Participate in the Piper Sandler 35th Annual Healthcare Conference

Zoetis is the largest player in the animal health industry, with high returns on capital and steadily growing margins. The company operates in two main categories: livestock, which is growing slowly, and the faster-growing companion market for pets. Management incentives align with shareholders.

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Cigna

Domino's Pizza

Lowe's

Microchip Technology

Monolithic Power Systems

MSCI

Rollins

Charles Schwab

Sirius XM Holdings Inc

SS&C Technologies Hlds

Skyworks Solutions

Tractor Supply

Texas Instruments

W. R. Berkley

The SPDR S&P 500 ETF posted its third consecutive losing month in October, the first time this has happened since I started tracking this series in September 2020. The top 15 dividend growth stocks for November offer an average dividend yield of 1.90% and appear to be about 40% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is outperforming VIG by 1.49% and SPY by 1.18%, on an annualized basis.

My Top 15 High Growth Dividend Stocks For November 2023

While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Zoetis (ZTS) Q3 Earnings

Zoetis' (ZTS) third-quarter 2023 earnings surpass estimates. However, revenues fall marginally short.

Zoetis' (ZTS) Q3 Earnings Beat, Revenues Miss by a Whisker

Zoetis Inc. (NYSE:ZTS ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Steve Frank - VP of IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Jon Block - Stifel Erin Wright - Morgan Stanley Nathan Rich - Goldman Sachs David Westenberg - Piper Sandler Michael Ryskin - Bank of America Brandon Vazquez - William Blair Balaji Prasad - Barclays Chris Schott - J.P. Morgan Operator Welcome to the Third Quarter 2023 Financial Results Conference Call and Webcast for Zoetis.

Zoetis Inc. (ZTS) Q3 2023 Earnings Conference Call Transcript

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today reported its financial results for the third quarter of 2023 and updated its guidance for full year 2023. The company reported revenue of $2.2 billion for the third quarter of 2023, an increase of 7% compared with the third quarter of 2022. On an operational1 basis, revenue for the third quarter of 2023 increased 8% compared with the third quarter of 2022, excluding the impact of foreign currency. Net income for the third quarter.

Zoetis Announces Third Quarter 2023 Results

Zoetis is an animal health company specializing in the development and manufacturing of veterinary pharmaceuticals and vaccines for both livestock and companion animals. For FY2023, the company has announced a $1 billion investment to enhance manufacturing capacity for monoclonal antibodies. This is the largest investment in its history. The company is sacrificing the short term to benefit in the long term. Which seems like a great decision and demonstrates an amazing corporate culture.

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Automatic Data Processing

Ares Management

Caterpillar

Coterra Energy

CubeSmart

Deere & Company

EOG Resources

Intuit

JPMorgan Chase & Co

Kinsale Capital Group

Mastercard

McKesson

Microsoft

NXP Semiconductors

Old Dominion Freight Line

PulteGroup

UnitedHealth Group

Vanguard Dividend Appreciation ETF

Vulcan Materials

We pick high-growth dividend stocks that have rapidly grown their dividends in the recent past rather than offering a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. We provide criteria for selecting high-growth dividend stocks, offering a step-by-step guide on structuring a portfolio based on this strategy.

Our Top 10 Picks For Dividend Growth Stocks - October 2023

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.375 per share for the fourth quarter of 2023. The dividend will be paid on Friday, December 1, 2023, to all holders of record of the Company's common stock as of the close of business on Wednesday, November 1, 2023. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. Afte.

Zoetis Declares Fourth Quarter 2023 Dividend

Cardinal Health

CrowdStrike

Genuine Parts

As uncertainty seems to dominate, it might be time to look for stocks to own during a downturn. For 10 straight months, investors enjoyed a strong comeback rally in the S&P 500.

The Top 7 Stocks to Own During a Downturn

Jazz Pharmaceuticals

Investors looking for stocks in the Medical - Drugs sector might want to consider either Jazz Pharmaceuticals (JAZZ) or Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?

JAZZ or ZTS: Which Is the Better Value Stock Right Now?

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again

Bank of America

Discover

September has historically been a bad month for equities, with the SPDR S&P 500 Trust ETF and Vanguard's Dividend Appreciation ETF both posting losses during the last 4 Septembers. The top 15 dividend growth stocks for October offer an average dividend yield of 1.94% and appear to be about 35% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is outperforming VIG by 2.92% and SPY by 2.34%, on an annualized basis.

My Top 15 High Growth Dividend Stocks For October 2023

Keurig Dr Pepper Inc

We believe that Zoetis stock (NYSE: ZTS), an animal health company, is a better pick than Keurig Dr Pepper stock (NASDAQ: KDP), given its better prospects.

Which Is A Better Pick – Keurig Dr Pepper Stock Or Zoetis?

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #earnings--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 2, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentatio.

Zoetis to Host Webcast and Conference Call on Third Quarter 2023 Financial Results

Zoetis Inc., the world's largest provider of animal medicines, vaccines, and diagnostic products, is capitalizing on the growing trend of pet pampering. The company dominates the companion animal and cattle markets, which are anti-cyclical and have strong growth potential. Zoetis expects to sustain above-average growth through innovation, strategic investments, and leveraging its broad product portfolio.

Zoetis Is An Impressive Healthcare Compounder

This monthly series of articles focuses on DGI stocks likely to provide a high rate of dividend growth rather than a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks. It offers a step-by-step guide on structuring a portfolio based on this strategy.

Our Top 10 Picks For Dividend Growth Stocks - September 2023

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?

Why Is Zoetis (ZTS) Down 1.3% Since Last Earnings Report?

Cintas Corp

These companies have delivered annual dividend growth of 24% to 35% over the last five years. Despite this rapid pace, the highest payout ratio of the group is only 39%.

4 Top Dividend Growth Stocks of the S&P 500 That Have Major Long-Term Potential for Investors

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DrivenToCare--Today, the Zoetis Foundation announced that it will distribute $2.6 million during its second round of 2023 grants, supporting six initiatives to help enable thriving professions and livelihoods for livestock farmers and veterinary professionals. The Zoetis Foundation has selected grantees that will help provide greater access to education and mental wellness resources, provide veterinary education debt relief funding, support diversity and inclusion efforts,.

Zoetis Foundation Announces $2.6 Million in Grants to Advance Opportunities for Veterinarians and Livestock Farmers

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, Sept. 12, 2023. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:55 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-pr.

Zoetis to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Dollar General

The summer stock market rally ended in August, with the SPDR S&P 500 Trust ETF posting a loss of 1.63%. The top 15 dividend growth stocks for September offer an average dividend yield of 1.86% and appear about 36% undervalued based on dividend yield theory. Since inception, September 2020, the watchlist is beating VIG by 3.91% and SPY by 3.12%.

My Top 15 High Growth Dividend Stocks For September 2023

USANA Health Sciences

Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?

USNA vs. ZTS: Which Stock Should Value Investors Buy Now?

DURHAM, N.C.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis: NEWS FACTS Today, Zoetis, the world leader in Animal Health, marked the official opening of its new building dedicated to diagnostics and biodevices research and development with a ribbon cutting ceremony at its site in Durham, N.C. The ceremony was attended by local officials, including North Carolina Secretary of Commerce Machelle Baker Sanders, North Carolina Representative Zack Hawkins and key company leaders including Zoetis CEO Kristin Peck, and Pres.

News for Zoetis Stock (ZTS)